325 related articles for article (PubMed ID: 35848197)
21. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
[TBL] [Abstract][Full Text] [Related]
22. The relationship between quality of life and the severity of psoriasis in Turkey.
Çakmur H; Derviş E
Eur J Dermatol; 2015 Apr; 25(2):169-76. PubMed ID: 25655046
[TBL] [Abstract][Full Text] [Related]
23. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life.
Gerdes S; Körber A; Biermann M; Karnthaler C; Reinhardt M
J Dermatolog Treat; 2020 Aug; 31(5):470-475. PubMed ID: 32202943
[No Abstract] [Full Text] [Related]
24. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
Gooderham M; Pinter A; Ferris LK; Warren RB; Zhan T; Zeng J; Soliman AM; Kaufmann C; Kaplan B; Photowala H; Strober B
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):855-865. PubMed ID: 35174556
[TBL] [Abstract][Full Text] [Related]
25. Short-Term Correlation of the Psoriasis Area Severity Index, the Nail Psoriasis Area Severity Index, and the Dermatology Life Quality Index, before and after Treatment, in Patients with Skin and Nail Psoriasis.
Prevezas C; Katoulis AC; Papadavid E; Panagakis P; Rigopoulos D
Skin Appendage Disord; 2019 Nov; 5(6):344-349. PubMed ID: 31799260
[TBL] [Abstract][Full Text] [Related]
26. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
Hjalte F; Carlsson KS; Schmitt-Egenolf M
Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
[TBL] [Abstract][Full Text] [Related]
27. Measurement properties of the patient global assessment numerical rating scale in moderate-to-severe psoriasis.
Yu N; Peng C; Zhou J; Gu J; Xu J; Li X; Bi X; Deng H; Li X; Ding Y; Shi Y
Br J Dermatol; 2023 Sep; 189(4):437-446. PubMed ID: 37310289
[TBL] [Abstract][Full Text] [Related]
28. The quality of life in Italian psoriatic patients treated with biological drugs.
Cozzani E; Borrini V; Pennella A; Burlando M; Cardo P; Rebora A; Parodi A
G Ital Dermatol Venereol; 2010 Dec; 145(6):709-12. PubMed ID: 21139547
[TBL] [Abstract][Full Text] [Related]
29. Epidermal barrier and oxidative stress parameters improve during in 311 nm narrow band UVB phototherapy of plaque type psoriasis.
Darlenski R; Hristakieva E; Aydin U; Gancheva D; Gancheva T; Zheleva A; Gadjeva V; Fluhr JW
J Dermatol Sci; 2018 Jul; 91(1):28-34. PubMed ID: 29610017
[TBL] [Abstract][Full Text] [Related]
30. PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol.
Walsh JA; Arledge T; Nurminen T; Peterson L; Stark J
J Rheumatol; 2018 Jul; 45(7):922-928. PubMed ID: 29717036
[TBL] [Abstract][Full Text] [Related]
31. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.
Norlin JM; Calara PS; Persson U; Schmitt-Egenolf M
J Dermatolog Treat; 2017 Sep; 28(6):500-504. PubMed ID: 28132580
[TBL] [Abstract][Full Text] [Related]
32. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab.
Torii H; Sato N; Yoshinari T; Nakagawa H;
J Dermatol; 2012 Mar; 39(3):253-9. PubMed ID: 22211581
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.
Seo SJ; Shin BS; Lee JH; Jeong H
J Dermatol; 2021 Jun; 48(6):807-817. PubMed ID: 33373480
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
Ioannides D; Antonakopoulos N; Georgiou S; Chasapi V; Katsantonis I; Drosos A; Rigopoulos D; Antoniou C; Anastasiadis G; Bassukas I; Ioannidou D; Protopapa A; Neofotistou O; Krasagakis K; Aronis P; Papageorgiou M; Lazaridou E; Patsatsi A; Lefaki I; Roussaki-Schulze AV; Satra F; Anagnostopoulos Z; Papakonstantis M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1838-1848. PubMed ID: 34036627
[TBL] [Abstract][Full Text] [Related]
35. The Impact of Hypertension, Diabetes, Lipid Disorders, Overweight/Obesity and Nicotine Dependence on Health-Related Quality of Life and Psoriasis Severity in Psoriatic Patients Receiving Systemic Conventional and Biological Treatment.
Karpińska-Mirecka A; Bartosińska J; Krasowska D
Int J Environ Res Public Health; 2021 Dec; 18(24):. PubMed ID: 34948777
[TBL] [Abstract][Full Text] [Related]
36. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
Petridis A; Panagakis P; Moustou E; Vergou T; Kallidis P; Mandekou-Lefaki I; Chaidemenos G; Sotiriadis D; Alexopoulou G; Haratsis Y; Antoniou C
J Eur Acad Dermatol Venereol; 2018 May; 32(5):768-775. PubMed ID: 29356149
[TBL] [Abstract][Full Text] [Related]
37. Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short "Washout" Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy.
Tampouratzi E; Sfaelos K; Talaiporou K; Douvali Τ; Katsantonis J
Acta Dermatovenerol Croat; 2023 Aug; 31(1):48-50. PubMed ID: 37843093
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
[TBL] [Abstract][Full Text] [Related]
39. Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life.
Walker F; Adamczyk A; Kellerer C; Belge K; Brück J; Berner T; Merten K; Núnez Gómez N; Neureither M; Röcken M; Ghoreschi K;
Br J Dermatol; 2014 Nov; 171(5):1197-205. PubMed ID: 24813676
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of an adjuvant Lactobacillus rhamnosus formula in improving skin lesions as assessed by PASI in patients with plaque psoriasis from a university-affiliated, tertiary-referral hospital in São Paulo (Brazil): a parallel, double-blind, randomized clinical trial.
Suriano ES; Souza MDM; Kobata CM; Santos FHY; Mimica MJ
Arch Dermatol Res; 2023 Aug; 315(6):1621-1629. PubMed ID: 36757438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
